Form 4: Supernus Pharmaceuticals SVP, Chief Medical Officer, Jonathan Rubin, Reports Changes in Beneficial Ownership

Jonathan Rubin, SVP, Chief Medical Officer of Supernus Pharmaceuticals, reports the vesting of Performance Share Units based on achievement of performance objectives.

Summary

• On December 23, 2024, Jonathan Rubin, SVP, Chief Medical Officer of Supernus Pharmaceuticals, reported changes in beneficial ownership.
• These changes involve the vesting of Performance Share Units (PSUs) awarded on February 23, 2023, and February 22, 2024.
• 750 PSUs from the February 23, 2023 award vested, and 1,875 PSUs from the February 22, 2024 award vested, both upon achievement of individual performance objectives.
• The performance objectives for the 2023 PSUs were established on June 12, 2023, and modified on December 12, 2024, while the objectives for the 2024 PSUs were established on June 24, 2024.
• Following these transactions, Rubin directly owns 750 and 1,875 Performance Share Units respectively.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting a routine transaction related to executive compensation. The vesting of PSUs suggests that performance objectives were met, which is mildly positive.

Positives

• The vesting of Performance Share Units indicates that individual performance objectives were met, which could be seen as a positive sign for the company's performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting of PSUs suggests continued focus on achieving performance objectives.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the holdings and transactions of company insiders. The vesting of PSUs is a common incentive mechanism used to align executive interests with shareholder value.

Comparison to Industry Standards

• Performance Share Units are a common form of executive compensation in the pharmaceutical industry, used by companies like Eli Lilly, Pfizer, and Johnson & Johnson.
• The vesting criteria based on individual performance objectives are also standard practice, aligning with industry norms for incentivizing key personnel.
• The specific number of PSUs and the performance metrics used to determine vesting would need to be compared to peer companies to assess the competitiveness of Supernus's compensation practices.

Stakeholder Impact

• The vesting of PSUs aligns executive compensation with company performance, potentially benefiting shareholders.
• The vesting of PSUs rewards the executive for achieving performance objectives.

Key Dates